Prevention
Funding: Featured Initiatives
Description: Supports focused microbicide innovation and development using the R21/R33 phased innovation and development mechanism. This is a milestone-driven program, wherein specific milestones are specified for the 2-year R21 portion of the award. If milestones are met and the research still meets program priorities and there are sufficient resources the award will be quickly transitioned to a 3-year R33.
Receipt dates: January 26, 2006
Awardees: TBD
Description: This program is designed to support preclinical discovery and development up to exploratory Phase I clinical trials aimed at advancing a candidate microbicide or strategy to more advanced clinical trials. It is funded through a collaborative U19 mechanism.
Receipt dates: Not currently available
List of Awardees:
-
Biosyn, Inc.
-
Case Western Reserve University
-
Magee-Womens Hospital
-
UCLA
-
Starpharma Pty LimitedOsel Inc.
-
Weill Medical College of Cornell University
Description: This program supports microbicide development from initial discovery through exploratory clinical testing (Phase I). It incorporates a commercial partner (private sector) in a multiproject environment under a cooperative agreement (U19) with NIH. It is focused on providing proof-of-concept for new microbicide strategies and approaches and supports critical path development of individual microbicides.
Receipt dates: September 23, 2004
Awardees: Starpharma Pty Limited
back to top